NIOX GroupCSSPF 77 Equity-to-Asset is 0.89 as of Dec. 2025, which is 11% above its 10-year median of 0.80. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 854 Medical Devices & Instruments companies, NIOX Group ranks better than 91.1% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. NIOX Group's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $90.50 Mil. NIOX Group's Total Assets for the quarter that ended in Dec. 2025 was $102.01 Mil.
Therefore, NIOX Group's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.89.
The historical rank and industry rank for NIOX Group's Equity-to-Asset or its related term are showing as below:
CSSPF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34 Med: 0.8 Max: 0.92
Current: 0.89
During the past 13 years, the highest Equity to Asset Ratio of NIOX Group was 0.92. The lowest was 0.34. And the median was 0.80.
CSSPF's Equity-to-Asset is ranked better than 91.1% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs CSSPF: 0.89
NIOX Group (OTCPK:CSSPF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
NIOX Group Equity-to-Asset Related Terms
NIOX Group Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for NIOX Group's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSSPF vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, NIOX Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where NIOX Group's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
NIOX Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group (CSSPF) has a Equity-to-Asset of 0.89 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on NIOX Group and its competitors. This is 11% above median its historical median of 0.80. Over the past decade, NIOX Group's Equity-to-Asset has ranged from 0.34 to 0.92. According to the industry distribution chart, NIOX Group ranks #76 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 8.9%.
Is NIOX Group's Equity-to-Asset too high?
NIOX Group's current Equity-to-Asset of 0.89 is 11% above median its 10-year median of 0.80. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 0.92. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. NIOX Group's value of 0.89 is 36.9% above this industry median. Based on the distribution chart, NIOX Group ranks #76 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #76 out of 854 companies for Equity-to-Asset. This places NIOX Group in the top 9% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.65. NIOX Group's value of 0.89 is 36.9% above this benchmark. Historically, NIOX Group's own Equity-to-Asset has ranged from 0.34 to 0.92 over the past decade. While the company's 10-year median is 0.80 vs. the industry median of 0.65, NIOX Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Equity-to-Asset of 0.89 is 36.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Equity-to-Asset is 0.89, which is 11% above median its own 10-year median of 0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.75 — trading 38% below its estimated fair value. The current Equity-to-Asset is 0.89, which is 11% above median its 10-year median of 0.80 and 36.9% above the Medical Devices & Instruments industry median of 0.65. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Equity-to-Asset is 0.89 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.75 is trading 38% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Equity-to-Asset: 0.89 (11% above median its 10-year median of 0.80)
GF Value™: $1.21 vs. price of $0.75 (38% below fair value)
Industry Position: 36.9% above the Medical Devices & Instruments median (#76 of 854)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
